Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous DC-CIK and NK cell therapy
- Development stage
- Unknown
- Lead developer
- Liaoning Medical Diagnosis and Treatment Technology Research and Development
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Subcutaneous
01
Overview
This autologous adoptive cellular immunotherapy is developed by Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd. for the treatment of advanced solid tumors. The therapy involves the ex vivo expansion and activation of a patient's own peripheral blood mononuclear cells (PBMCs) into three distinct immune cell populations: dendritic cells (DC), cytokine-induced killer (CIK) cells, and natural killer (NK) cells. Dendritic cells are administered subcutaneously to present tumor antigens and stimulate a specific T-cell response, while CIK and NK cells are infused intravenously to provide non-MHC-restricted cytotoxic activity against cancer cells. This combined approach is designed to enhance the body's systemic immune function, target residual lesions, and inhibit tumor proliferation in patients with lung, liver, colorectal, and breast cancers.
- Other names
- autologous DC-CIK cellsautologous NK cellsautologous immune cell therapyDC-CIK therapy
02
Targets
MICB (Major histocompatibility complex class i-related protein B)
Beyond the preview
Go deeper on autologous DC-CIK and NK cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous DC-CIK and NK cell therapy.